Objective: To explore the effect of entecavir on patients with decompensated chronic hepatitis B cirrhosis. Methods: From October 2007 to December 2019, 100 patients with decompensated chronic hepatitis B cirrhosis who were treated in our hospital were selected to carry out this study. The clinical data of the patients were analyzed. According to whether entecavir treatment was carried out, 100 patients were divided into two groups, 50 cases in the control group and 50 cases in the observation group. The control group was treated with conventional drugs, and the observation group was treated with entecavir. Liver function indexes, liver fibrosis indexes, HBV-DNA negative conversion rate and incidence of adverse reactions were compared between the two groups. Results: Compared with the control group, the liver function indexes of the observation group were lower, P < 0.05; Compared with the control group, the observation group was better, P < 0.05; The negative rate of HBV-DNA in the observation group was lower than that in the control group (P < 0.05); There was no difference in the incidence of adverse reactions between the two groups, P > 0.05. Conclusion: Entecavir can not only improve the liver function, but also enhance the short-term treatment effect, without increasing adverse reactions, and has high safety, which is worthy of recommendation.